This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization
Scientific Reports Open Access 28 February 2022
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Passweg JR, Baldomero H, Bader P, Bonini C, Duarte RF, Dufour C, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52:811–7.
Morin-Zorman S, Loiseau P, Taupin J-L, Caillat-Zucman S. Donor-specific Anti-HLA antibodies in allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:307.
Kongtim P, Cao K, Ciurea SO. Donor specific anti-HLA Antibody and risk of graft failure in haploidentical stem cell transplantation. Adv Hematol. 2016;2016:4025073.
Chang Y-J, Luznik L, Fuchs EJ, Huang X-J. How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation? J Hematol OncolJ Hematol Oncol. 2016;9:35.
Ciurea SO, Thall PF, Milton DR, Barnes TH, Kongtim P, Carmazzi Y, et al. Complement-binding donor-specific anti-hla antibodies and risk of primary graft failure in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:1392–8.
Leffell MS, Jones RJ, Gladstone DE. Donor HLA-specific Abs: to BMT or not to BMT? Bone Marrow Transplant. 2015;50:751–8.
Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland M-L, Leguay T, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123:3739–49.
Cartron G, Trappe RU, Solal-Céligny P, Hallek M. Interindividual variability of response to rituximab: from biological origins to individualized therapies. Clin Cancer Res. 2011;17:19–30.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Garnier, A., Delbos, F., Guillaume, T. et al. Rituximab for second desensitization in patients with rebound of donor-specific anti-HLA antibodies before T-replete haplo-transplant using high-dose post-transplant cyclophosphamide. Bone Marrow Transplant 53, 1044–1047 (2018). https://doi.org/10.1038/s41409-018-0107-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-018-0107-7
This article is cited by
-
Inhibition of spleen tyrosine kinase decreases donor specific antibody levels in a rat model of sensitization
Scientific Reports (2022)
-
Rituximab for desensitization during HLA-mismatched stem cell transplantation in patients with a positive donor-specific anti-HLA antibody
Bone Marrow Transplantation (2020)